Opus Genetics, Inc. (NASDAQ: IRD) reported Q2 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $2.88 million versus the consensus estimate of $4.04 million.

For earnings history and earnings-related data on Opus Genetics, Inc. (IRD) click here.